Kornimate/medical-research-clean huggingface dataset:
real time myocardial perfusion echocardiography for coronary allograft vasculopathy

Conditions: Cardiac Allograft Vasculopathy

Summary: is real-time myocardial perfusion echocardiography (rtmpe) a feasible and effective non-invasive method to detect significant coronary allograft vasculopathy in pediatric and adult cardiac transplant recipients? will perfusion deficits correlate with significant coronary artery stenosis identified by standard stress echocardiography and invasive coronary angiography (ica), and identify diffuse small vessel disease more effectively than current non-invasive techniques?

heart transplant recipients are susceptible to developing a unique disease that causes blockages in the arteries of the transplanted heart (coronary arteries) called coronary allograft vasculopathy (cav). because cav often progresses without symptoms, transplant recipients undergo regular surveillance testing so that cav can be detected and treatment can be offered before significant damage to the transplanted heart occurs. current tests used to detect cav are either invasive (with risk of complications) or may not be able to detect cav in its early stages. myocardial contrast perfusion echocardiography is a safe non-invasive diagnostic test that may be well suited for detecting cav, however has not been well studied in heart transplant recipients. this study examines the ability of myocardial contrast perfusion echocardiography to detect cav in adult and pediatric heart transplant recipients, and compare those results to current standard testing strategies such as invasive coronary angiography (ica) and standard stress echocardiography. this will help determine whether myocardial contrast perfusion echocardiography is a better test for regular surveillance of cav in adult and pediatric transplant recipients.

Eligibility criteria:
inclusion: * cardiac transplant recipients (\> or equal to 10 months post transplant) * clinically followed at mayo clinic, rochester minnesota exclusion: * standard contraindications to the use of ultrasound contrast and pharmacologic stress * recent (\< 3 months) hospitalization for heart failure, acute coronary syndrome or allograft rejection * multi-organ transplant known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts * hypersensitivity to perflutren
trial to investigate the efficacy of olmesartan in paroxysmal atrial fibrillation

Conditions: Heart Disease; Arrhythmia; Atrial Fibrillation

Summary: hypothesis: blocking the angiotensin (at) ii type 1 receptor (olmesartan) reduces the incidence of episodes of atrial fibrillation in patients with paroxysmal atrial fibrillation during 12 months by more than 25% compared to standard medication without angiotensin ii type 1 receptor. a total of 422 subjects will be included in the two study groups. the treatment arm will receive 40mg olmesartan per day, the remaining patients will receive placebo. follow-up is 12 months. daily tele-ecg recordings will determine the cardiac rhythm and asymptomatic episodes of atrial fibrillation (af) every day. concomitant therapy with av-nodal blocking drugs are allowed during the study. in case of severe af-induced symptoms, an antiarrhythmic "recovery medication" (amiodarone) is allowed during follow-up.

double-blind, central randomization, two treatment groups, stratified by beta-blocker use. 211 patients in each treatment arm.

Eligibility criteria:
inclusion criteria: * documented paroxysmal atrial fibrillation: ecg documentation of atrial fibrillation at least in one ecg recorded during the last 2 months prior to randomization plus additional ecg recording of sinus rhythm at least 12 hours after the above mentioned ecg documentation. * age ≥ 18 * patient informed orally and in writing * written informed consent of the patient exclusion criteria: * strong clinical evidence for therapy with at ii/ace inhibitors * at ii/ace inhibitor therapy within the last month * therapy with antiarrhythmic agents of class i or class iii within the last month, therapy with amiodarone within the last 3 months * direct current (dc) cardioversion within the last 3 months * symptomatic bradycardia * implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardiac algorithm in use * cardiac surgery or cardiac catheter ablation within the last 3 months * typical angina pectoris symptoms at rest or during exercise * known coronary artery disease with indication for intervention * valvular disease \> ii degree * left ventricular ejection fraction \< 40% * diastolic blood pressure \> 110mm hg at rest * symptomatic arterial hypotension * known renal artery stenosis * serum creatinine \> 1.8 mval/l * relevant hepatic or pulmonary disorders * hyperthyroidism manifested clinically and in laboratory * known drug intolerance for at ii inhibitors * females who are pregnant or breast feeding * females of childbearing potential who are not using a scientifically accepted method of contraception * participation in a clinical trial within the last 30 days * drug addiction or chronic alcohol abuse * legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical study * evidence of an uncooperative attitude

Keywords: atrial fibrillation angiotensin ii angiotensin receptor antagonist drug controlled clinical trial
vildagliptin compared to pioglitazone in combination with metformin in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. the purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of pioglitazone in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.


Eligibility criteria:
inclusion criteria: * on a stable dose of metformin as defined by the protocol * blood glucose criteria must be met * body mass index (bmi) in the range 22-45 exclusion criteria: * history of type 1 diabetes * pregnancy or lactation * evidence of significant diabetic complications * serious cardiovascular events within the past 6 months * laboratory value abnormalities as defined by the protocol * known sensitivity to pioglitazone * other protocol-defined exclusion criteria may apply

Keywords: type 2 diabetes vildagliptin
women on breast cancer health belıefs and screenıng behavıors

Conditions: Breast Cancer Female

Summary: method: it was conducted in a randomized controlled experimental type. the population of the study consisted of 2426 women over the age of 20 living in a family health center in erzurum between october 2021 and september 2022. the sample of the study consisted of 252 women with 0.05 margin of error and 95% confidence level, according to the sample size calculation formula used in cases where the universe is known. within the framework of the exclusion criteria of the study, 52 women were excluded from the study and 200 women were included in the randomization.

persons in the experimental group will be trained 6 times with an interval of 2 weeks via an online platform (zoom, etc.). no training will be given to the control group, and the post-test data will be collected by re-administering the two groups with the mid-test created via google forms and containing the scales immediately after the training, and the "health belief model scale in breast cancer screening" and "breast cancer screening beliefs scale" two months later.

Eligibility criteria:
inclusion criteria: -being over 18 years old * being literate, * computer can be used, * internet is accessible, * not getting breast cancer before, exclusion criteria: * having received training on breast cancer before * having a history of breast cancer in first degree relatives * those who did not attend all of the online trainings in the experimental group
study to evaluate ospemifene in patients with moderate to severe vaginal dryness due to menopause

Conditions: Vaginal Dryness

Summary: the objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (qd) compared with placebo in treatment of vulvo-vaginal atrophy (vva) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (mbs) of vva.


Eligibility criteria:
inclusion criteria: * subject is postmenopausal. * subject has moderate to severe vaginal dryness as the self-reported mbs of vva. exclusion criteria: * subject has clinically significant abnormal findings in the physical examination. * subject has a body mass index (bmi) equal to or greater than 38 kg/m\^2 * subject has uncontrolled hypertension. * subject has clinically significant abnormal findings in the gynecological examination other than signs of vaginal atrophy. * subject has uterine/vaginal bleeding of unknown origin. * subject has a vaginal infection requiring medication (may be treated and be eligible for study).

Keywords: vulvo-vaginal atrophy menopause
effect of patient education on kidney recipients knowledge, coping and quality of life

Conditions: Renal Recipients

Summary: for patients with end-stage kidney disease, transplantation is the treatment of choice, offering improved quality of life by restored metabolism and freedom from dialysis. however, demands regarding the acquirement of knowledge in life post transplantation are high. in order to reduce rejection episodes, graft loss and the negative consequences of life-long immunosuppressive medication, it is essential for kidney recipients to possess knowledge about important aspects regarding immunosuppressive medication, graft surveillance and the benefit of specific lifestyle behavior. consequently, patient education is required for this patient group. this randomized controlled trial is investigating the effect of a structured patient education program on kidney recipients' knowledge, coping and quality of life


Eligibility criteria:
inclusion criteria: * being over 18 * recently had a kidney transplant * able to speak, understand and read norwegian * mentally able to participate in the study
evaluation of the results of lateral suspension surgeries performed with the v-notes (vaginal-natural orifice transluminal endoscopic surgery) technique

Conditions: Pelvic Organ Prolapse

Summary: it was aimed to evaluate the quality of life and sexual function of patients by pre- and postoperative pop-q (pelvic organ prolapse quantification) staging and pisq-12 (pelvic organ prolapse/urinary incontinence sexual questionnaire) test of patients who underwent lateral suspension operation with v-notes (vaginal-natural orifice transluminal endoscopic surgery) technique.

notes technically means a surgical intervention performed by entering the abdomen through one of the body's natural openings such as mouth, anus, vagina, and urethra. with the flexible endoscope, a hole is made in organs such as stomach, colon, vagina, bladder, and the peritoneal cavity is entered and the area to be studied is provided by filling air. with the v-notes (vaginal vaginal-natural orifice transluminal endoscopic surgery) method we will apply, we reject the bladder from the cervix and reach to abdominal cavity by piercing the visceral peritoneum. the abdomen will be viewed via trocars placed in this region and a lateral suspension operation, which is a kind of suspension surgery of pelvic organ prolapsus, will be performed.the pop-q staging that will be performed before the lateral suspension operation with the v-notes technique will be compared with the pop-q staging 6 after the operation. in addition, pelvic organ prolapse/urinary incontinence sexual function questionnaire (pisq-12) test will be used for the evaluation of pelvic organ prolapse, urinary incontinence and sexual function in the same intervals.

Eligibility criteria:
inclusion criteria: * patients with more than 2nd and 3rd degree uterine prolapsus * patients with more than 2nd and 3rd degree cystocele exclusion criteria: * having endometriosis * having a history and/ or active pelvic inflammatory disease * having uterine fibroids * having an adnexal cyst with risk of malignancy * being pregnant

Keywords: pelvic organ prolapse lateral suspension v-notes pop-q pısq-12
reward effects on cognition, motor skills, and motivation in children

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)

Summary: this interventional study aimed to aimed to evaluate the effects of rewards on cognitive function, motor skills, and motivation in 8- to 10-year-old children with adhd following 3- and 6-week interventions.

research problem: children with attention-deficit/hyperactivity disorder (adhd) are inattentive and distractible, which often makes it difficult for physiotherapists to keep them interested, as prolonged activity often causes boredom. the aim of this study was to determine the effects of reward on cognitive function, motor skills and motivation in 8-10 year old children with adhd after 3 and 6 week interventions. objectives of the study: 1. to compare the cognitive function of children receiving conventional physiotherapy with that of children receiving reward therapy. 2. to compare the motor skills of the children receiving conventional physiotherapy with those of the children receiving the reward. 3. to compare the motivation of children receiving conventional physiotherapy with that of children receiving rewards. the hypothesis of the study is that exercise with rewards improves cognitive function, motor skills and motivation better than conventional physiotherapy in children aged 8 to 10 years with attention deficit disorder. research methods: the study included 60 boys diagnosed with adhd. age: 8-10 years. subjects were randomly divided into reward and conventional physiotherapy groups. in both groups, subjects performed exercises for balance and coordination for 3 times per week for 45 min, but in one group subjects received a reward using virtual reality.

Eligibility criteria:
inclusion criteria: 1. diagnosis of adhd confirmed by a neurologist; 2. male gender; 3. age between 8 and 10 years. 4. ability to read and write; 5. patient's willingness to attend physiotherapy sessions; exclusion criteria: 1. claustrophobia; 2. neurological disorders (e.g., autism spectrum disorder, depression, obsessive-compulsive disorder, tourette's syndrome); 3. chronic medical conditions (e.g., cancer, diabetes, cardiovascular diseases); 4. previous treatment for adhd (e.g., pharmacological therapy, cognitive behavioral therapy) within the last six months; 5. medication use.

Keywords: attention motor skills motivation reward-based therapy
study on the efficacy of he and therapeutic group factors on cr and qol

Conditions: Cardiac Rehabilitation

Summary: this randomised study evaluates the efficacy of health education and therapeutic group factors on cardiac rehabilitation and quality of life in coronary patients attending cardiac rehabilitation programmes in extremadura.

cardiac rehabilitation has been shown to be effective in improving the quality of life of patients who have suffered a cardiovascular event, as well as in preventing future cardiovascular events, demonstrating an increase in survival of between 20% and 30%, with a class ia recommendation. due to the prevalence of cardiovascular disease, both nationally and globally, it is important to study the benefits of these cardiac rehabilitation programmes in order to encourage their use. however, several studies have shown that for the programme to be effective, 5% to 10% weight loss must be achieved in patients, adequate nutritional education must be implemented, and behavioural and psychological intervention programmes must be incorporated in order to have an impact on adherence, psychological well-being, and coping with exercise intolerance. this project aims to study the effectiveness of health education and therapeutic group factors in cardiac rehabilitation and on quality of life in coronary patients in cardiac rehabilitation units in extremadura, including in the analysis anthropometric and body composition, nutritional, cognitive, emotional and lifestyle factors, which could act as mediators of cardiac function, reactivity to neuro-cardiovascular stress, anxiety, depression, anger-hostility, rehospitalisation, adherence, and adherence to treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of coronary heart disease, referred to the "cardiac prevention and rehabilitation unit". exclusion criteria: * patients with disabling psychiatric disorders. * existence of pacemaker or automatic defibrillator. * presence of pregnancy or breastfeeding. * presence of medical conditions related to oncological conditions requiring chronic treatment with drugs or other substances. * any condition that, in the opinion of the investigators, would disqualify the subject from participation in the study.

Keywords: quality of life cardiovascular disease health education
early weight bearing tarsometatarsal fusion study

Conditions: Hallux Valgus

Summary: a prospective, randomized, controlled trial comparing early weight bearing versus non weight bearing following modified lapidus arthrodesis

the purpose of this prospective randomized control trial is to assess outcomes in patients who undergo modified lapidus arthrodesis and whose postoperative management includes early weight bearing on heel (in a boot) and compare it to standard of care non weight bearing post operative management.

Eligibility criteria:
inclusion criteria: * patient has signed the institutional review board approved informed consent form specific to this study prior to enrollment * failure of conservative treatment (i.e. non-surgical action, consisting of footwear modification in the form of shoes with wide toe boxes, padded inserts, activity modifications and pain control medications) * patients who underwent lapidus procedure with or without other procedures of the first ray (i.e., muscle-tendon procedures, distal metatarsal osteotomy, akin procedure) * patient older than 18 years of age * patient is able to give informed consent * patient is independent, ambulatory, and agrees to comply with all postoperative visits exclusion criteria: * patient has a pre-existing condition which may cause impairment of healing and bone fusion * any significant pathology that, in the opinion of investigator, makes the patient unsuitable for study * patients who underwent lapidus arthrodesis in conjunction with other procedures that did not focus on the first pedal ray with the exception of harvesting autogenous ipsilateral calcaneal bone graft

Keywords: lapidus arthrodesis early weight bearing first tarsometatarsal arthrodesis
treatment of ventilator associated pneumonia in pediatric intensive care unit

Conditions: Ventilator Associated Pneumonia

Summary: treatment of ventilator associated pneumonia in pediatric intensive care unit according to the american guidelines

to assess the degree of adherence of pediatric physicians of assiut university children hospital to the american guidelines of treatment of ventilator associated pneumonia in pediatric intensive care unit searching for defects,obstacles,or need to improve health service.

Eligibility criteria:
inclusion criteria: - children of both sexes. - aged from 1 month to 18 years. - the patients are fulfilling the diagnostic criteria of ventilator associated pneumonia. exclusion criteria: - patients aged less than 1 month. - patients who are intubated and mechanically ventilated for less than 48 hours.
outcome of embryos transferred after initial chaotic results on pgt-a

Conditions: Infertility

Summary: this is a retrospective review of treatment outcomes from fertility clinics in the prelude network who have used igenomix for pgt-a and have transferred embryos with initial chaotic results, regardless if re-biopsy was performed.

primary objective: to observe the outcomes of embryos transferred with initial "chaotic" results on pgt-a via igenomix. hypothesis: the transfer of chaotic embryos can result in clinical pregnancy, as defined by fetal heartbeat at 6-8 weeks gestation. furthermore, these transfers may also result in live birth and expand reproductive potential for patients seeking ivf with pgt-a.

Eligibility criteria:
inclusion criteria: * patients that conducted pgt-a via igenomix who have transferred an embryo with an initial chaotic result. exclusion criteria: * patients who had multiple embryo transfer.
weight loss as therapy for heart failure with preserved ejection fraction

Conditions: Heart Failure, Diastolic; Weight Loss

Summary: the purpose of this study is to examine the efficacy of an intensive, supervised, lifestyle modification program on symptoms and signs of heart failure as well as laboratory and echocardiographic measures of cardiac structure and function. this will be a 6 month trial in 50 patients with a clinical diagnosis of heart failure with preserved ejection fraction (hfpef). patients will be enrolled in the medical university of south carolina weight management 15 week lifestyle change program which will involve weekly visits that rotate among the clinical specialities (dietary, exercise and behavioral) and scheduled visits with the research registered nurse. each patients baseline data will be used as the control and compared with the same measurements at the 6 month end point.


Eligibility criteria:
inclusion criteria: * bmi \> 30 * able to perform 6 minute hall walk test * left ventricular ejection fraction \>45% * diagnosis of heart failure with preserved ejection fraction (hfpef) ; confirmation of hfpef based on 1 major or 3 minor criteria listed below. major: 1. elevated bnp \>200 2. cardiogenic pulmonary edema 3. pulmonary capillary wedge pressure at rest \>15 mmhg or with exercise \>25 mmhg using invasive right heart pressure measurement minor: 1. left atrial enlargement (volume \>68 ml) 2. increased left ventricular wall thickness (\>1.1cm) by echocardiography 3. e/e' \>15 4. intermediate level of bnp, 60-199 exclusion criteria: * uncontrolled blood pressure * severe chronic obstructive pulmonary disease (oxygen or steroid dependent) * recurrent major depression. presence or history of suicide behavior, and current substantial depressive symptoms. antidepressant drugs are allowed if the dose has been stable for 3 months * other major psychiatric illness (schizophrenia, bipolar, dementia) * significant hepatic dysfunction * untreated hypothyroidism or hyperthyroidism * history of drug or alcohol abuse or dependency within the past 12 months * acute coronary syndrome without revascularization in the past 12 months * acute coronary syndrome with revascularization in the past 6 months * cerebrovascular accident or transient ischemic attack in the past 6 months * cancer or terminal illness with life expectancy \< 3 years * history of medical noncompliance * significant anemia (hgb \<9) * life threatening or uncontrolled arrhythmia * hemodynamically relevant valvular heart disease * infiltrative heart disease including cardiac amyloidosis, sarcoidosis, fabry's disease * genetic hypertrophic cardiomyopathy * significant pericardial disease * clinically relevant neuromuscular disease * pregnant or may become pregnant in the next 6 months * prior major organ transplant or intent to transplant ( on the transplant list) * pacemaker dependant * clinically significant congenital heart disease that may be cause of symptoms